- Home
- GLTO vs QTI Comparison
GLTO vs QTI Comparison
Compare GLTO & QTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- QTI
- Stock Information
- Founded
- GLTO 2011
- QTI 2012
- Country
- GLTO Denmark
- QTI United States
- Employees
- GLTO N/A
- QTI N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- QTI
- Sector
- GLTO Health Care
- QTI
- Exchange
- GLTO Nasdaq
- QTI NYSE
- Market Cap
- GLTO 9.5M
- QTI 11.2M
- IPO Year
- GLTO 2020
- QTI N/A
- Fundamental
- Price
- GLTO $5.81
- QTI $0.51
- Analyst Decision
- GLTO Buy
- QTI
- Analyst Count
- GLTO 1
- QTI 0
- Target Price
- GLTO $10.00
- QTI N/A
- AVG Volume (30 Days)
- GLTO 16.5K
- QTI 200.8K
- Earning Date
- GLTO 11-01-2024
- QTI 11-13-2024
- Dividend Yield
- GLTO N/A
- QTI N/A
- EPS Growth
- GLTO N/A
- QTI N/A
- EPS
- GLTO N/A
- QTI N/A
- Revenue
- GLTO N/A
- QTI $4,037,118.00
- Revenue This Year
- GLTO N/A
- QTI N/A
- Revenue Next Year
- GLTO N/A
- QTI N/A
- P/E Ratio
- GLTO N/A
- QTI N/A
- Revenue Growth
- GLTO N/A
- QTI 10884.16
- 52 Week Low
- GLTO $5.62
- QTI $0.41
- 52 Week High
- GLTO $23.50
- QTI $14.40
- Technical
- Relative Strength Index (RSI)
- GLTO 25.82
- QTI 42.72
- Support Level
- GLTO $5.62
- QTI $0.49
- Resistance Level
- GLTO $6.94
- QTI $0.67
- Average True Range (ATR)
- GLTO 0.34
- QTI 0.10
- MACD
- GLTO 0.02
- QTI -0.00
- Stochastic Oscillator
- GLTO 11.27
- QTI 26.85
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About QTI QT IMAGING HOLDINGS INC
QT Imaging Holdings Inc is engaged in the research, development and commercialization of an automated breast imaging system producing high-resolution transmission ultrasound images.